Chi Yan

7PUBLICATIONS
10CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jan 12, 2026
RAS/MEK/PI3K pathway inhibition augments response to CD40 agonism by targeting CD11b+ Bregs thereby overcoming melanoma PD1-resistance.

Chi Yan, Weifeng Luo, Jinming Yang

|Jul 29, 2023
Generation of Orthotopic Patient-Derived Xenografts in Humanized Mice for Evaluation of Emerging Targeted Therapies and Immunotherapy Combinations for Melanoma.

Chi Yan, Caroline A Nebhan, Nabil Saleh

|Jul 09, 2022
Immunomodulatory Properties of PI3K/AKT/mTOR and MAPK/MEK/ERK Inhibition Augment Response to Immune Checkpoint Blockade in Melanoma and Triple-Negative Breast Cancer.

Zhizhu Zhang, Ann Richmond, Chi Yan

|Jan 21, 2022
Proximity of immune and tumor cells underlies response to BRAF/MEK-targeted therapies in metastatic melanoma patients.

Chi Yan, Sheau-Chiann Chen, Gregory D Ayers

|Jun 02, 2021
Inhibition of the PI3K/mTOR Pathway in Breast Cancer to Enhance Response to Immune Checkpoint Inhibitors in Breast Cancer.

Chi Yan, Jinming Yang, Nabil Saleh

|Nov 12, 2020
Targeted Deletion of CXCR2 in Myeloid Cells Alters the Tumor Immune Environment to Improve Antitumor Immunity.

Jinming Yang, Chi Yan, Anna E Vilgelm

Pageof 2

Frequent Collaborators

6 joint publications

Ann Richmond

2 joint publications

Nabil Saleh

1 joint publications

Jun Wang

1 joint publications

Sheau-Chiann Chen